All In Biotech

Drug Trial Radar · NCT05951049

A Study of AT-02 in Subjects With Systemic Amyloidosis.

A Phase 2, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of AT-02

Last checked: Nov 19, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Sep 21, 2023

Primary completion

Sep 28, 2026

Study completion Sep 28, 2026

Sponsor

Lead sponsor
Attralus, Inc.Industry
Sponsor type
Industry
Collaborators
Novotech (Australia) Pty Limited
First posted
Jul 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2 open-label extension study to evaluate the long-term safety, tolerability, and clinical activity of AT-02. AT-02 is an investigational medicinal product being developed to treat systemic amyloidosis.

Conditions

  • Amyloidosis; Systemic

Interventions

  • AT02Drug

    Dosage Form: Solution for injection/infusion Dosage level: Different dose levels of AT02 Route of Administration: Intravenous use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence, frequency, and severity of Treatment-emergent adverse events (TEAEs) as assessed National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 5.0)Time frame: Up to 112 weeks
  2. To assess the safety and tolerability of AT-02 through change from baseline in clinical laboratory resultsTime frame: Up to 112 weeks

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Kansas City

    Kansas City, Kansas

  • Cleveland Clinic

    Cleveland, Ohio

  • OHSU (Oregon Health & Science University)

    Portland, Oregon

  • Penn Presbyterian Medical Center

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.